TrialBMC neurology2020

Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine.

Virginia L Stauffer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.